CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Incidence and Outcomes of Acute Coronary Syndrome After Transcatheter Aortic Valve Replacement Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial Treatment of coronary bifurcation lesions, part I: implanting the first stent in the provisional pathway. The 16th expert consensus document of the European Bifurcation Club Optical coherence tomography and C-reactive protein in risk stratification of acute coronary syndromes In vivo comparison of lipid-rich plaque on near-infrared spectroscopy with histopathological analysis of coronary atherectomy specimens Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial Prognostic impact of baseline glucose levels in acute myocardial infarction complicated by cardiogenic shock-a substudy of the IABP-SHOCK II-trial

Original ResearchVolume 72, Issue 25, December 2018

JOURNAL:J Am Coll Cardiol. Article Link

Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring

JD Mitchell, N Fergestrom, BF Gage et al. Keywords: atherosclerotic cardiovascular disease; calcium score; cardiovascular risk; primary prevention; screening

ABSTRACT


BACKGROUND - Compared with traditional risk factors, coronary artery calcium (CAC) scores improve prognostic accuracy for atherosclerotic cardiovascular disease (ASCVD) outcomes. However, the relative impact of statins on ASCVD outcomes stratified by CAC scores is unknown.

 

OBJECTIVES -  The authors sought to determine whether CAC can identify patients most likely to benefit from statin treatment.

 

METHODS - The authors identified consecutive subjects without pre-existing ASCVD or malignancy who underwent CAC scoring from 2002 to 2009 at Walter Reed Army Medical Center. The primary outcome was first major adverse cardiovascular event (MACE), a composite of acute myocardial infarction, stroke, and cardiovascular death. The effect of statin therapy on outcomes was analyzed stratified by CAC presence and severity, after adjusting for baseline comorbidities with inverse probability of treatment weights based on propensity scores.

 

RESULTS -  A total of 13,644 patients (mean age 50 years; 71% men) were followed for a median of 9.4 years. Comparing patients with and without statin exposure, statin therapy was associated with reduced risk of MACE in patients with CAC (adjusted subhazard ratio: 0.76; 95% confidence interval: 0.60 to 0.95; p = 0.015), but not in patients without CAC (adjusted subhazard ratio: 1.00; 95% confidence interval: 0.79 to 1.27; p = 0.99). The effect of statin use on MACE was significantly related to the severity of CAC (p < 0.0001 for interaction), with the number needed to treat to prevent 1 initial MACE outcome over 10 years ranging from 100 (CAC 1 to 100) to 12 (CAC >100).

 

CONCLUSIONS -  In a largescale cohort without baseline ASCVD, the presence and severity of CAC identified patients most likely to benefit from statins for the primary prevention of cardiovascular diseases.